Table 6.
Analysis of the combined effects of doxorubicin and Rosco on human colorectal cancer cell lines
| Combined treatment of doxorubicin and Rosco |
Combination interaction at various durations of treatment in human colorectal cancer cells1 |
||||||||
| SW48 | SW1116 | SW837 | |||||||
| 2 d | 4 d | 6 d | 2 d | 4 d | 6 d | 2 d | 4 d | 6 d | |
| Dox 0.5 IC50 + Rosco 1.0 μg/mL | ant | ant | ant | syn | syn | syn | syn | syn | syn |
| Dox 1.0 IC50 + Rosco 10 μg/mL | ant | ant | ant | syn | syn | syn | syn | syn | syn |
| Dox 2.0 IC50 + Rosco 15 μg/mL | ant | ant | ant | syn | syn | syn | syn | syn | syn |
| Dox 3.0 IC50 + Rosco 20 μg/mL | ant | add | add | syn | syn | add | syn | syn | add |
| Dox 4.0 IC50 + Rosco 25 μg/mL | ant | add | add | syn | ant | add | syn | ant | ant |
1
The data are based on the mean of absorbance measurements of 3 independent experiments; ant: Antagonistic; add: Additive; syn: Synergistic.